Trial Profile
A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2020
Price :
$35
*
At a glance
- Drugs Afabicin (Primary) ; Afabicin (Primary) ; Linezolid; Vancomycin
- Indications Abscess; Bacterial skin diseases; Cellulitis; Staphylococcal infections; Wound infections
- Focus Therapeutic Use
- Sponsors Debiopharm
- 03 Aug 2020 Results published in the Antimicrobial Agents and Chemotherapy
- 10 Jan 2017 Results published in the Debiopharm Group Media Release
- 19 Oct 2016 Status changed from active, no longer recruiting to completed.